EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dopaminergic and Opioid Systems Interact to Produce Peripheral Antinociception in Mice

Bárbara F G Queiroz, Walace C P Barra, Flávia C S Fonseca, Audrey L Irie, Thiago R L Romero, Igor D G Duarte

Journal of Integrative Neuroscience · 2025

DOI: 10.31083/jin44311 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Integrative Neuroscience, 2025. Verfasst von Bárbara F G Queiroz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pain and Analgesia, Department of Pharmacology, Institute of Biological Sciences, Federal University of Minas Gerais, 31270901 Belo Hor…. Hauptthemen laut MEDLINE: Dopamine, Nociception, Receptors, Opioid, Analgesics, Opioid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Comissão de Aperfeiçoamento de Pessoal do Nível Superior (CAPES), Conselho Nacional de Pesquisa (CNPq), Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The overall pain experience results from the balance between the nociceptive pathway and the body’s endogenous modulation of nociception. The interaction of these systems reduces nociception. Therefore, this study aimed to evaluate how the opioid and dopaminergic systems collaborate to inhibit pain at the peripheral level.

Methods

Swiss mice (30–40 g) had their pain sensitivity increased through paw administration of the prostaglandin E2 (2 μg). They then received opioid and dopaminergic receptor antagonists and agonists, along with an inhibitor of endogenous opioid peptide degradation and a dopamine (DA) reuptake inhibitor. The nociceptive threshold was measured using the paw withdrawal test. Groups were compared using one-way analysis of variance (ANOVA), with p < 0.05 considered significant.

Results

The nonselective opioid receptor antagonist naloxone (50 μg/paw) and the selective κ nor-BNI (200 μg/paw; nor-Binaltorphimine) and δ naltrindole (60 μg/paw) receptor antagonists reversed the antinociception caused by peripheral administration of DA (80 ng/paw), but not the μ-opioid receptor antagonist CTOP (20 μg/paw; D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2). The antinociception induced by a submaximal dose of DA (5 ng/paw) was enhanced by bestatin (400 μg/paw), an inhibitor of endogenous opioid peptide degradation. Conversely, peripheral antinociception from submaximal doses of the μ-, δ-, and κ-opioid agonists DAMGO (0.25 μg/paw; [D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin), SNC 80 (5 μg/paw; (+)-4-[(αR)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide), and bremazocine (200 ng/paw) was increased by the DA reuptake inhibitor GBR 12783 (16 μg/paw; 1-(2-Diphenylmethoxyethyl)-4-(3-phenyl-2-propenyl)-piperazine). Furthermore, the antinociception from these agonists’ maximum doses was reversed by dopaminergic D2 (remoxipride, 4 μg/paw) and D3 (U99194, 16 μg/paw; 2,3-Dihydro-5,6-dimethoxy-N, N-dipropyl-1H-inden-2-amine) receptor antagonists, but not by the D4 (L-745, 870, 16 μg/paw; 3-(4-[4-Chlorophenyl]piperazin-1-yl)-methyl-1H-pyrrolo[2,3-b]pyridine trihydrochloride) receptor antagonist.

Conclusions

Overall, the data suggest that opioid-mediated antinociception depends on the activation of the dopaminergic system. This demonstrates that pain modulation can be enhanced through the interaction of these systems. Controlling pain at a peripheral level by activating endogenous pathways could be a promising approach to pain management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DopamineNociceptionReceptors, OpioidAnalgesics, OpioidPainAnimalsMiceMaleNarcotic AntagonistsDopamine AntagonistsNaltrexoneDinoprostoneSomatostatinDisease Models, AnimalPain MeasurementPain ThresholdNaloxoneEnkephalin, Ala(2)-MePhe(4)-Gly(5)-Dopamine Agonists

Stichwörter der Autor:innen

dopamineopioidpain modulationperipheral antinociception

Substanzen

Narcotic AntagonistsDopamineReceptors, OpioidDopamine AntagonistsAnalgesics, OpioidNaltrexoneDinoprostoneSomatostatinNaloxoneEnkephalin, Ala(2)-MePhe(4)-Gly(5)-

Autor:innen und Institutionen

  • Laboratory of Pain and Analgesia, Department of Pharmacology, Institute of Biological Sciences, Federal University of Minas Gerais, 31270901 Belo Horizonte, Minas Gerais, Brazil.

Förderung

  • Comissão de Aperfeiçoamento de Pessoal do Nível Superior (CAPES)
  • Conselho Nacional de Pesquisa (CNPq)
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG)

Zitieren

APA

Queiroz, B. F. G., Barra, W. C. P., Fonseca, F. C. S., Irie, A. L., Romero, T. R. L., & Duarte, I. D. G. (2025). Dopaminergic and Opioid Systems Interact to Produce Peripheral Antinociception in Mice. Journal of Integrative Neuroscience. https://doi.org/10.31083/jin44311

Vancouver

Queiroz BFG, Barra WCP, Fonseca FCS, Irie AL, Romero TRL, Duarte IDG. Dopaminergic and Opioid Systems Interact to Produce Peripheral Antinociception in Mice. Journal of Integrative Neuroscience. 2025. doi:10.31083/jin44311

BibTeX
@article{Queiroz2025,
  author = {Queiroz, Bárbara F G and Barra, Walace C P and Fonseca, Flávia C S and Irie, Audrey L and Romero, Thiago R L and Duarte, Igor D G},
  title = {Dopaminergic and Opioid Systems Interact to Produce Peripheral Antinociception in Mice},
  journal = {Journal of Integrative Neuroscience},
  year = {2025},
  doi = {10.31083/jin44311}
}
Kostenlos starten →